Drug news
GSK files at FDA for H5N1 subtype Influenza vaccine
GSK has submitted a regulatory application to the FDA seeking approval for an H5N1 influenza vaccine. The Biologics License Application seeks approval for the �active immunisation for the prevention of disease in persons 18 years of age and older at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine� for use as directed by the U.S. Government. H5N1 pandemic influenza vaccine, manufactured in Quebec, was approved in Europe on 4 March 2011 under the brand name, Pumarix.